- Home
- IMMX vs BIVI Comparison
IMMX vs BIVI Comparison
Compare IMMX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- BIVI
- Stock Information
- Founded
- IMMX 2014
- BIVI 2013
- Country
- IMMX United States
- BIVI United States
- Employees
- IMMX N/A
- BIVI N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- BIVI Health Care
- Exchange
- IMMX Nasdaq
- BIVI Nasdaq
- Market Cap
- IMMX 46.8M
- BIVI 45.1M
- IPO Year
- IMMX 2021
- BIVI N/A
- Fundamental
- Price
- IMMX $1.67
- BIVI $3.05
- Analyst Decision
- IMMX Strong Buy
- BIVI Strong Buy
- Analyst Count
- IMMX 1
- BIVI 2
- Target Price
- IMMX $7.00
- BIVI $40.00
- AVG Volume (30 Days)
- IMMX 89.1K
- BIVI 3.3M
- Earning Date
- IMMX 11-12-2024
- BIVI 11-13-2024
- Dividend Yield
- IMMX N/A
- BIVI N/A
- EPS Growth
- IMMX N/A
- BIVI N/A
- EPS
- IMMX N/A
- BIVI N/A
- Revenue
- IMMX N/A
- BIVI N/A
- Revenue This Year
- IMMX N/A
- BIVI N/A
- Revenue Next Year
- IMMX $200.00
- BIVI N/A
- P/E Ratio
- IMMX N/A
- BIVI N/A
- Revenue Growth
- IMMX N/A
- BIVI N/A
- 52 Week Low
- IMMX $1.26
- BIVI $1.04
- 52 Week High
- IMMX $7.75
- BIVI $56.54
- Technical
- Relative Strength Index (RSI)
- IMMX 50.69
- BIVI 54.28
- Support Level
- IMMX $1.65
- BIVI $3.00
- Resistance Level
- IMMX $1.93
- BIVI $3.85
- Average True Range (ATR)
- IMMX 0.16
- BIVI 0.38
- MACD
- IMMX 0.01
- BIVI -0.01
- Stochastic Oscillator
- IMMX 42.55
- BIVI 45.36
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.